4-(2-甲酰基苯甲酰基)吗啉 | 84538-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-(2-甲酰基苯甲酰基)吗啉
• 英文名称: 2-(morpholine-4-carbonyl)benzaldehyde
• CAS: 84538-50-1
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: GOJDFUAZNPZWPM-UHFFFAOYSA-N

物化性质

• 熔点：
  79-82 °C
• 沸点：
  420.4±40.0 °C(Predicted)
• 密度：
  1.236±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-甲酰基苯甲酰基)吗啉 在 水 、 hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 吗啉 、 邻羧基苯甲醛
  参考文献：
  名称：

  Bowden, Keith; Hiscocks, Simon P.; Reddy, M. Komal, Journal of the Chemical Society. Perkin transactions II, 1997, # 2, p. 1133 - 1138

  摘要：

  DOI：
• 作为产物：
  描述：

  3-羟基异苯并呋喃-1(3H)-酮 在 氯化亚砜 、 三氯化铁 作用下， 以 丙酮 为溶剂， 反应 8.0h， 生成 4-(2-甲酰基苯甲酰基)吗啉
  参考文献：
  名称：

  Effect of nucleophilicity and leaving group ability on the SN2 reactions of amines with (acyloxy)alkyl .alpha.-halides: a product distribution study

  摘要：

  DOI：

  10.1021/jo00153a002

文献信息

• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。
• Mild Chemical and Biological Synthesis of Donor-Acceptor Flanked Reporter Stilbenes: Demonstration of a Physiological Wittig Olefination Reaction
  作者：David McLeod、James McNulty

  DOI：10.1002/ejoc.201201042

  日期：2012.11

  Unprecedented chemoselectivity is reported for the Wittig olefination reaction leading to the formation of reporter stilbenes under physiological conditions.

  据报道，Wittig 烯化反应具有前所未有的化学选择性，导致在生理条件下形成报道二苯乙烯。
• [EN] MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT LA PROTEINE KINASE-2 ACTIVEE PAR LA PROTEINE KINASE ACTIVEE PAR DES AGENTS MITOGENES
  申请人：PHARMACIA CORP

  公开号：WO2004058762A1

  公开（公告）日：2004-07-15

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶2（MK-2）的化合物。描述了使用这些化合物来抑制MK-2，以及预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制剂化合物。还描述了包含本MK-2抑制剂化合物的治疗组合物、药物组合物和试剂盒。
• Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
  申请人：Pharmacia Corporation

  公开号：US20040209897A1

  公开（公告）日：2004-10-21

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2（MK-2）的化合物。本文还描述了使用这些化合物来抑制MK-2并预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制化合物。本文还描述了包含本MK-2抑制化合物的治疗组合物、制药组合物和试剂盒。
• HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES
  申请人：Zhi Lin

  公开号：US20120295904A1

  公开（公告）日：2012-11-22

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  本实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。本实施例还涉及使用这些化合物来治疗各种状况、疾病和疾病，例如造血系统状况和疾病。